세계 맨틀세포 림프종 시장 – 2023-2030

Overview
Global Mantle Cell Lymphoma Market reached US$ 2.1 billion in 2022 and is expected to reach US$ 2.9 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2023-2030.
Mantle cell lymphoma (MCL) is one of the B-cell non-Hodgkin lymphomas that occur due to tumors in the lymph nodes, which enter the blood and spread to the bone marrow, spleen, digestive tract, and liver. This type of cancer usually grows gradually before starting to grow more rapidly. Mantle cell lymphoma quickly spreads throughout your lymphatic system and to other body parts.
About 1 in 10 people with mantle cell lymphoma carry a slow-growing version of the condition. Mantle cell lymphoma (MCL) is associated with a poor prognosis. It exhibits a moderately aggressive course similar to intermediate-grade non-Hodgkin lymphoma (NHL). Unlike intermediate-grade lymphomas, it is rarely curable with currently available standard treatment.
Furthermore, the growing development of targeted therapy drugs, rising expenditure in the oncology sector, and increase in drug development strategies and discoveries are a few factors that drive the market in the forthcoming period.
Dynamics
Increasing Product Launches
In recent years, new cell types and technologies have been used to overcome challenges posed by current treatments and the nature of the targeted diseases, thus enabling us to treat and cure severe disorders. Lymphomas are a heterogeneous group of malignancies that arise from the clonal proliferation of B cell, T-cell, and subsets of lymphocytes at different stages of maturation. The products launched for a specific lymphoma are used for treating the subsets.
In March 2023, AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China.
Rising Clinical Trials
The number of registered clinical oncology clinical trials has steadily increased. For instance, according to data from the WHO International Clinical Trials Registry Platform (ICTRP), in 2013, approximately 19,211 trials were registered in this field, and by 2022, that number had grown to 26,396. Recent years have witnessed numerous breakthroughs in oncology clinical trials, spanning immunotherapies, precision medicine, gene therapy, and combination therapy.
The Lymphoma Academic Research Organisation and Institute of Cancer Research collaborated to conduct phase 2 clinical trials to compare the efficacy of Ibrutinib/anti-CD20 Ab versus Ibrutinib/anti-CD20 Ab/Venetoclax given as fixed duration combinations in newly diagnosed Mantle Cell Lymphoma (MCL) patients (≥ 18 years and < 80 years of age). The estimated completion date is September 30, 2031.
Onset of Side Effects Due to Targeted Therapies
Targeted therapy drugs have different side effects than standard or traditional chemotherapy. Angiogenesis inhibitors often target vascular endothelial growth factor (VEGF) proteins. Bevacizumab (Avastin) turns off the signal for skin cells to grow normally, making it harder for them to retain moisture. Hand-foot syndrome (HFS) has been linked to many cancer treatment drugs, including some targeted therapies. Some targeted drugs, especially angiogenesis inhibitors, can raise blood pressure. Increased risks of certain infections and cancers are also observed, according to the American Cancer Society.
Segment Analysis
The global mantle cell lymphoma is segmented based on diagnosis, drug/therapy, end user, and region.
The Targeted Therapy Segment Accounted for Approximately 37.8% of the Market Share
Developing targeted agents with low toxicity profiles for treating relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor in augmenting the mantle cell lymphoma treatment market growth. The introduction of the novel targeted agent’s ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of the mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), according to James N. Gerson, MD.
For instance, a Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age by PrECOG, LLC. In collaboration with Genentech, Inc., expected to be completed by March 2025 and a Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma by Washington University School of Medicine in collaboration with Acerta Pharma BV estimated to be completed by November 2025.
Geographical Analysis
North America accounted for Approximately 39.3% of the Market Share in 2022
Clinical trials are essential to improving cancer treatment, especially in highly lethal cancers like mantle cell lymphoma. Major cancer organizations, including the National Comprehensive Cancer Network, American Society of Clinical Oncology, and Association of Community Cancer Centers, endorse that all cancer patients should consider and have the opportunity to participate in clinical trials.
M.D. Anderson Cancer Center is conducting phase 2 clinical trials. This phase II trial studies the side effects of acalabrutinib and rituximab and its effect in treating patients with previously untreated mantle cell lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. Giving acalabrutinib and rituximab may help to control mantle cell lymphoma in elderly patients. The estimated completion date is August 30, 2026.
Furthermore, according to the rare disease organization, MCL usually occurs at 60 to 70 years old, and since the United States has a large pool of geriatric population is expected to dominate the global market.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global mantle cell lymphoma market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.
The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of cancer-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market. Furthermore, due to the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with mantle cell lymphoma undetected, negatively impacting the global mantle cell lymphoma market growth during the pandemic.
By Diagnosis
• Laboratory exams
• Imaging Tests
• Bone marrow Biopsy
• Others
By Drug/Therapy
• Chemotherapy
o Acalabrutinib
o ibrutinib
o pirtobrutinib
o zanubrutinib
o Others
• Targeted Therapy
o Monoclonal Antibody Therapy
• Immunotherapy
o CAR T-cell therapy
• Stem Cell Transplantation
• Others
By End User
• Hospitals
• Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2023, Gilead Sciences, Inc. and Kite Pharma, a Gilead Company presented 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11.
• In January 2023, Loxo Lilly, the oncology unit of Eli Lilly and Company, announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
• On 16 August 2022, FDA accepted the supplemental Biologics License Application for Roche’s Policy combination for people with previously untreated diffuse large B-cell lymphoma.
Competitive Landscape
The major global players in the mantle cell lymphoma market include Kite Pharma, Inc. (Gilead Sciences, Inc.), F. Hoffman La Roche Ltd, Abbvie, Inc., Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, Johnson and Johnson, and BeiGene GmBH among others.
Why Purchase the Report?
• To visualize the global mantle cell lymphoma market segmentation based on diagnosis, drug/therapy, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of mantle cell lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global mantle cell lymphoma market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies